This supports the notion that BET isoform activity promotes malignancy preferentially in IDHmut glioma and suggests that pan-BET inhibitors would be more useful as cancer therapeutics in IDHmut glioma, though our TCGA data also points to the promise of BRD4-selective inhibitors in the treatment of IDHmut glioma. This evidence concerns the gene BRD4 and central nervous system cancer.